Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -1.49%31.47B | -4.02%31.95B | -16.40%7.62B | 0.09%8.59B | -10.23%7.81B | 15.07%7.94B | 14.67%33.28B | 26.69%9.11B | 29.66%8.58B | 11.44%8.7B |
| Cost of revenue | -2.73%26.78B | -3.66%27.53B | -12.12%6.65B | -2.04%7.29B | -9.65%6.84B | 12.56%6.75B | 9.16%28.58B | 12.53%7.56B | 20.70%7.45B | 9.60%7.57B |
| Gross profit | 6.23%4.69B | -6.20%4.42B | -37.35%971M | 14.12%1.29B | -14.06%966M | 31.60%1.19B | 65.29%4.71B | 228.39%1.55B | 152.90%1.13B | 25.59%1.12B |
| Operating expense | 4.33%3.93B | 7.51%3.77B | 6.57%908M | 9.92%964M | 0.43%936M | 13.76%959M | 3.70%3.5B | 0.47%852M | 5.41%877M | 7.62%932M |
| Staff costs | 0.18%1.66B | 8.09%1.66B | ---- | ---- | ---- | ---- | 1.19%1.53B | ---- | ---- | ---- |
| Selling and administrative expenses | -3.42%536M | -9.17%555M | ---- | ---- | ---- | ---- | 31.97%611M | ---- | ---- | ---- |
| -Selling and marketing expense | 10.31%107M | 8.99%97M | ---- | ---- | ---- | ---- | 71.15%89M | ---- | ---- | ---- |
| -General and administrative expense | -6.33%429M | -12.26%458M | ---- | ---- | ---- | ---- | 27.01%522M | ---- | ---- | ---- |
| Research and development costs | 44.08%487M | 25.19%338M | ---- | ---- | ---- | ---- | -21.05%270M | ---- | ---- | ---- |
| Depreciation and amortization | -5.26%108M | -5.00%114M | ---- | ---- | ---- | ---- | 13.21%120M | ---- | ---- | ---- |
| -Depreciation | -5.26%108M | -5.00%114M | ---- | ---- | ---- | ---- | 13.21%120M | ---- | ---- | ---- |
| Other operating expenses | 3.26%1.14B | 13.70%1.1B | ---- | ---- | ---- | ---- | 1.78%971M | ---- | ---- | ---- |
| Operating profit | 17.23%762M | -46.06%650M | -90.97%63M | 28.52%329M | -84.38%30M | 286.44%228M | 327.36%1.21B | 285.64%698M | 166.67%256M | 562.07%192M |
| Net non-operating interest income (expenses) | -104.41%-139M | 11.69%-68M | -35.29%-23M | 37.50%-10M | 27.27%-16M | 13.64%-19M | -18.46%-77M | 5.56%-17M | -14.29%-16M | -22.22%-22M |
| Non-operating interest income | 4.76%22M | 5.00%21M | -28.57%5M | -11.11%8M | 150.00%5M | 50.00%3M | 11.11%20M | 40.00%7M | 125.00%9M | -33.33%2M |
| Non-operating interest expense | 80.90%161M | -8.25%89M | 16.67%28M | -28.00%18M | -12.50%21M | -8.33%22M | 16.87%97M | 4.35%24M | 38.89%25M | 14.29%24M |
| Net investment income | 187M | 0 | -96.36%4M | -159.74%-46M | 93.10%168M | -42.50%46M | -116.67%-65M | 523.08%110M | ||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | -96.35%11M | 301M | 0 | 206M | 0 | 95M | 0 | 0 | 0 | 0 |
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 192.47%86M | -143.87%-93M | 0 | -121.12%-64M | 2,300.00%132M | -3,925.00%-161M | 140.61%212M | 83.83%-81M | 1,542.86%303M | -6M |
| Less:Impairment of capital assets | -92.86%1M | -22.22%14M | -40.00%3M | 0.00%3M | -33.33%4M | 0.00%4M | 12.50%18M | 400.00%5M | --3M | --6M |
| Less:Other special charges | -563.46%-241M | 111.74%52M | 86.86%-18M | --51M | ---138M | --157M | -538.61%-443M | -244.21%-137M | ---- | ---- |
| Less:Write off | 470.37%154M | -87.32%27M | -92.96%15M | --10M | ---- | ---- | -47.41%213M | --213M | --0 | ---- |
| Other non-operating income (expenses) | 852.94%128M | -117.71%-17M | -107.32%-6M | -575.00%-27M | 14.29%8M | -27.27%8M | 21.52%96M | 38.98%82M | 42.86%-4M | -70.83%7M |
| Income before tax | 33.59%1.03B | -51.81%771M | -89.52%76M | -8.88%431M | -43.57%158M | -13.11%106M | 267.71%1.6B | 195.52%725M | 203.73%473M | 3,011.11%280M |
| Income tax | 76.07%287M | -46.73%163M | -40.00%81M | -112.07%-7M | 25.49%64M | -59.68%25M | 104.00%306M | 550.00%135M | 0.00%58M | 82.14%51M |
| Net income | 22.24%742M | -53.09%607M | -101.02%-6M | 5.54%438M | -58.33%95M | 33.33%80M | 217.21%1.29B | 181.07%591M | 180.90%415M | 1,240.00%228M |
| Net income continuous operations | 22.20%743M | -53.01%608M | -100.85%-5M | 5.54%438M | -58.95%94M | 35.00%81M | 217.21%1.29B | 180.93%590M | 180.74%415M | 1,305.26%229M |
| Noncontrolling interests | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to the company | 22.24%742M | -53.05%607M | -101.02%-6M | 5.54%438M | -58.33%95M | 33.33%80M | 217.12%1.29B | 180.93%590M | 180.90%415M | 1,240.00%228M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 22.24%742M | -53.05%607M | -101.02%-6M | 5.54%438M | -58.33%95M | 33.33%80M | 217.12%1.29B | 180.93%590M | 180.90%415M | 1,240.00%228M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 32.84%72.04 | -49.86%54.23 | -98.05%0.96 | 11.35%38.64 | -58.61%7.91 | 33.86%6.72 | 217.16%108.16 | 180.96%49.33 | 180.72%34.7 | 1,258.18%19.11 |
| Diluted earnings per share | 32.84%72.04 | -49.86%54.23 | -101.18%-0.5823 | 11.39%38.64 | -58.50%7.91 | 33.86%6.72 | 217.16%108.16 | 180.93%49.3174 | 180.69%34.6893 | 1,240.00%19.0582 |
| Dividend per share | 8.33%13 | -14.29%12 | -11.11%8 | 0 | -20.00%4 | 0 | 75.00%14 | 200.00%9 | 0 | 0.00%5 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |